ESMO Asia 2025 – Oric’s first-line gamble
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ADC slides on latest Zynlonta update
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Black Diamond picks brain cancer for silevertinib
Though lung cancer looks promising a partner is now needed.
Adlai puts its faith in pan-RAS
The company’s AN9025 will shortly enter phase 1.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Imvax’s brain fail
But the group still hopes to get IGV-001 approved based on overall survival data.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
FDA red and green lights: November 2025
The agency approved eight oncology products over the month.
